TL;DR
This study uncovers a novel epigenetic pathway in gastric cancer (GC) where the E3 ubiquitin ligase RNF180 suppresses tumor growth and metastasis. RNF180 achieves this by promoting the degradation of DNMT1, a key enzyme in DNA methylation, which in turn reduces the aberrant methylation of the tumor suppressor gene PCDH10, thereby restoring its expression. This RNF180/DNMT1/PCDH10 axis presents a promising therapeutic target for GC.
What Problem Does This Paper Address?
Gastric cancer (GC) is a major cause of cancer-related mortality, and its progression is often driven by the silencing of tumor suppressor genes (TSGs) through aberrant DNA hypermethylation. While Protocadherin 10 (PCDH10) is known to be a TSG that is frequently downregulated in various cancers, including GC, the precise mechanisms behind its silencing in GC remained unclear. This paper aims to elucidate a novel epigenetic regulatory pathway that controls PCDH10 expression and its role in GC progression, with the ultimate goal of identifying new therapeutic targets.
Methods
The researchers employed a multi-pronged approach combining transcriptomic, molecular, and in vivo/in vitro experimental techniques. Key methods included:
- Gene Expression Analysis: Using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases, as well as RT-PCR and western blotting, to quantify PCDH10, RNF180, and DNMT1 mRNA and protein levels in GC tissues and cell lines.
- DNA Methylation Analysis: Employing Next-Generation Sequencing (NGS) methylation analysis to assess the methylation status of the PCDH10 promoter region.
- Functional Assays:
- Cell Proliferation and Apoptosis: CCK-8 assays, colony formation assays, and flow cytometry were used to evaluate the impact of PCDH10 overexpression on GC cell growth and apoptosis.
- Cell Migration and Invasion: Transwell assays were conducted to assess the effect of PCDH10 on cell migration and invasion.
- In Vivo Xenograft Models: Lentiviral vectors were used to stably overexpress PCDH10 in GC cells, which were then injected into nude mice to evaluate tumor growth and metastasis.
- Protein Interaction and Degradation Studies:
- Immunofluorescence and Co-immunoprecipitation (Co-IP): To confirm the physical interaction between RNF180 and DNMT1.
- Cycloheximide (CHX) Chase Assays: To determine the effect of RNF180 on DNMT1 protein stability and degradation.
- Ubiquitination Assays: To assess the ubiquitination status of DNMT1 in the presence or absence of RNF180.
- Gene Ontology (GO) and KEGG Pathway Analysis: To identify the biological processes and pathways affected by the differential expression of genes in response to PCDH10 or RNF180 manipulation.
Datasets
The study utilized publicly available datasets and collected patient samples:
- The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases: For analyzing PCDH10 expression levels in GC tissues and normal samples.
- Broad Institute CCLE database: For assessing global methylation levels of PCDH10 in GC cells.
- Epigenome-wide association studies (EWAS) database: For investigating PCDH10 methylation in GC tissues.
- Patient Samples: 142 paraffin-embedded advanced gastric adenocarcinoma specimens and paired adjacent noncancerous tissue samples were collected for prognostic evaluation. An additional 176 samples were used for tissue microarray construction. Frozen GC and adjacent normal mucosa samples were also collected for RT-PCR and western blot analysis.
Key Insights and Ideas
- RNF180 as a Tumor Suppressor in GC: The study strongly implicates RNF180 as a tumor suppressor in GC, with its overexpression correlating with better prognosis and reduced metastasis.
- PCDH10 Silencing Mechanism: The core finding is that PCDH10 is silenced in GC primarily through DNMT1-mediated promoter hypermethylation.
- RNF180's Role in DNMT1 Degradation: A critical insight is that RNF180, an E3 ubiquitin ligase, directly interacts with DNMT1 and promotes its ubiquitination and subsequent proteasomal degradation. This is a novel mechanism for regulating DNMT1 activity.
- The RNF180/DNMT1/PCDH10 Axis: The study elegantly connects these players, demonstrating that RNF180's action on DNMT1 leads to reduced PCDH10 methylation and restored PCDH10 expression, ultimately suppressing GC progression.
- Prognostic Significance: Both PCDH10 and RNF180 expression levels, and their inverse correlation with DNMT1, were found to be significant predictors of patient prognosis in GC.
Key Results
- PCDH10 expression was significantly downregulated in GC tissues and cell lines compared to normal counterparts.
- Low PCDH10 expression was significantly correlated with lymph node metastasis and poor prognosis in GC patients.
- Overexpression of PCDH10 inhibited GC cell proliferation, migration, invasion, and induced apoptosis both in vitro and in vivo.
- PCDH10 promoter hypermethylation was observed in GC tissues and cells, and this methylation was significantly reduced upon DNMT1 knockdown.
- RNF180 overexpression led to decreased DNMT1 protein levels, while RNF180 knockdown increased DNMT1 levels, suggesting post-transcriptional regulation.
- RNF180 directly interacted with DNMT1 and promoted its ubiquitination and degradation.
- RNF180 overexpression significantly increased PCDH10 expression, and RNF180 knockdown increased PCDH10 methylation.
- RNF180 expression was positively correlated with PCDH10 expression and negatively correlated with DNMT1 expression in GC tissues.
- Patients with high co-expression of PCDH10 and RNF180 showed the best prognosis, while those with low RNF180 and high DNMT1 had the worst prognosis.
Limitations and Future Work
- Specific Ubiquitination Sites: While the study demonstrates that RNF180 promotes DNMT1 ubiquitination, the specific lysine residues on DNMT1 targeted by RNF180 are not detailed. Future work could focus on identifying these sites.
- In Vivo Validation of the RNF180/DNMT1/PCDH10 Axis: While the study provides strong evidence for the RNF180/DNMT1/PCDH10 axis, further in vivo studies specifically manipulating RNF180 and observing the downstream effects on DNMT1 and PCDH10 in a tumor context would be valuable.
- Therapeutic Translation: The authors suggest the RNF180/DNMT1/PCDH10 axis as a potential therapeutic target. Future research could explore strategies to modulate RNF180 activity or DNMT1 degradation for GC treatment.
- Broader Cancer Types: While focused on GC, exploring whether this regulatory axis is conserved in other cancer types could broaden its clinical relevance.
Summary updated